Empyrean Capital Partners, LP Innoviva, Inc. Transaction History
Empyrean Capital Partners, LP
- $2.01 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding INVA
# of Institutions
229Shares Held
79.2MCall Options Held
37.6KPut Options Held
300-
Black Rock Inc. New York, NY9.63MShares$184 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT7.28MShares$139 Million34.93% of portfolio
-
Franklin Resources Inc San Mateo, CA6.75MShares$129 Million0.04% of portfolio
-
Putnam Investments LLC Boston, MA6.27MShares$120 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.23MShares$119 Million0.0% of portfolio
About Innoviva, Inc.
- Ticker INVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 69,706,000
- Market Cap $1.33B
- Description
- Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...